4.3 Article

Circulating interleukin-15 and RANTES chemokine in Parkinson's disease

Journal

ACTA NEUROLOGICA SCANDINAVICA
Volume 116, Issue 6, Pages 374-379

Publisher

WILEY
DOI: 10.1111/j.1600-0404.2007.00894.x

Keywords

IL-15; RANTES; serum; Elisa; Parkinson's disease; immunological disturbances; L-dopa treatment

Ask authors/readers for more resources

Interleukin-15 promotes T-cell proliferation, induction of cytolytic effector cells including natural killer (NK) and cytotoxic cells and stimulates B-cell to proliferate and secrete immunoglobulins. RANTES is a C-C beta chemokine with strong chemoattractant activity for T lymphocytes and monocytes. Objectives - The objective of our study was to find out whether IL-15 and RANTES are involved in the possible inflammatory reactions of PD. Patients and methods - We measured by immunoassay serum IL-15 and RANTES levels in 41 patients with PD in comparison with serum levels in 19 healthy subjects age and sex-matched. IL-15 and RANTES levels were correlated with sex, age, disease duration. H-Y stage and the UPDRS III score in all the studied groups and were also correlated with treatment status in PD patients. Results - The PD group presented with significantly increased RANTES levels as compared to the control group (P = 0.0009). No difference was observed as regards IL-15 levels. A strong and significant correlation between RANTES levels and UPDRS III score was observed in PD patients (R-s = 0.42, P = 0.007). Untreated patients had significantly higher RANTES levels as compared to the controls. Conclusions - Our findings may suggest a recruitment of activated monocytes, macrophages and T lymphocytes to sites of inflammation in the central nervous system of PD patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available